- June 28, 2021NEW YORK, June 28, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- June 10, 2021NEW YORK, June 10, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- June 1, 2021NEW YORK, June 1, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- May 17, 2021BEAT-COV begrüßt Initiative des Bundes für 300 Millionen Euro Förderprogramm für versorgungsnahe COVID-19-Medikamente Deutschland, 17. Mai 2021 – Das Bundesministerium…
- May 6, 2021– EMPhASISCohort 2Interim Analysis Confirmed 30 mg Dose of IMU-838 as Most Appropriate for Planned Phase 3 Program in Relapsing-Remitting…
- April 15, 2021– Preplanned Interim Analysis of 12-Week MRI Data from 10 mg IMU-838 Dose and Placebo, in Combination with Existing 30…
- April 13, 2021NEW YORK, April 13, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- March 31, 2021NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 – Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective…
- March 2, 2021NEW YORK, March 2, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- February 26, 2021– Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to Begin in the Second Half of 2021– –…
